It’s been a disastrous year for Portola Pharmaceuticals Inc (NASDAQ:PTLA) thus far, as the company has shed over 60% of its value year-to-date. However, far from spurring investors to flee the stock, it appears to have created a great buy-low opportunity, as evidenced by James Flynn‘s Deerfield Management hiking its stake in the company to 3.09 million shares as of March 24. That’s the same day that shares cratered by over 25% after the company announced that results from a phase III trial showed that its blood-clot treatment betrixaban had failed to show any statistical improvement over the current standard treatment for the condition, Lovenox. Shares fell by another 6% on March 28.
Deerfield’s updated position represents a big hike from the 683,749 shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) that it owned on December 31. It was one of 24 hedge funds in our database that were long the stock at that time, with Jason Karp’s Tourbillon Capital and Samuel Isaly’s OrbiMed Advisors among the other investors with long positions in it.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 3,089,785 | 0 | 3,089,785 | 3,089,785 | 5.48% |
| Deerfield Management Company | 0 | 3,089,785 | 0 | 3,089,785 | 3,089,785 | 5.48% |
| Deerfield Partners | 0 | 1,340,437 | 0 | 1,340,437 | 1,340,437 | 2.38% |
| Deerfield Special Situations Fund | 0 | 43,337 | 0 | 43,337 | 43,337 | 0.08% |
Follow James E. Flynn's Deerfield Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 12 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Portola Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
737010108
(CUSIP Number)
March 24, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
(Page 1 of 12 Pages)
__________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 12 – SEC Filing
| CUSIP No. | 737010108 | 13G | Page 2 of 12 Pages |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 3,089,785 (1) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 3,089,785 (1) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,089,785 (1) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.48% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
(1) Comprised of shares of common stock held by Deerfield Partners, L.P., Deerfield International Master Fund, L.P. and Deerfield Special Situations Fund, L.P., of which Deerfield Mgmt, L.P. is the general partner.
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 12 – SEC Filing
| CUSIP No. | 737010108 | 13G | Page 3 of 12 Pages |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Management Company, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 3,089,785 (2) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 3,089,785 (2) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,089,785 (2) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.48% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
(2) Comprised of shares of common stock held by Deerfield Partners, L.P., Deerfield International Master Fund, L.P. and Deerfield Special Situations Fund, L.P., of which Deerfield Management Company, L.P. is the investment advisor.
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 12 – SEC Filing
| CUSIP No. | 737010108 | 13G | Page 4 of 12 Pages |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Partners, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 1,340,437 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 1,340,437 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,340,437 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.38% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 12 – SEC Filing
| CUSIP No. | 737010108 | 13G | Page 5 of 12 Pages |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Special Situations Fund, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 43,337 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 43,337 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 43,337 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.08% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 12 – SEC Filing
| CUSIP No. | 737010108 | 13G | Page 8 of 12 Pages |
| Item 1(a). | Name of Issuer: | |
| Portola Pharmaceuticals, Inc. | ||
| Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
| 270 E. Grand Avenue South San Francisco, CA 94080 | ||
| Item 2(a). | Name of Person Filing: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P. | ||
| Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
| Item 2(c). | Citizenship: | |
| Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Partners, L.P. – Delaware limited partnerships; Deerfield International Master Fund, L.P. – British Virgin Islands limited partnership; James E. Flynn – United States citizen | ||
| Item 2(d). | Title of Class of Securities: | |
| Common Stock | ||
| Item 2(e). | CUSIP Number: | |
| 737010108 | ||
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | o | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | o | Investment company registered under Section 8 of the Investment Company Act. |
| (e) | o | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | o | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 12 – SEC Filing
| CUSIP No. | 737010108 | | Page 10 of 12 Pages |
| (iii) | Sole power to dispose or to direct the disposition of: | All Reporting Persons – 0 | |||
| (iv) | Shared power to dispose or to direct the disposition of: | Deerfield Mgmt, L.P. – 3,089,785 Deerfield Management Company, L.P. – 3,089,785 Deerfield Partners, L.P. – 1,340,437 Deerfield International Master Fund, L.P. – 1,706,011 Deerfield Special Situations Fund, L.P. – 43,337 James E. Flynn – 3,089,785 |
**See footnotes on cover pages which are incorporated by reference herein.
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.
| | |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
| | N/A |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
| | N/A |
| Item 8. | Identification and Classification of Members of the Group. |
If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.
| | See Exhibit B |
| Item 9. | Notice of Dissolution of Group. |
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
| | N/A |
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 12 – SEC Filing
| CUSIP No. | 737010108 | | Page 11 of 12 Pages |
| Item 10. | Certifications. |
“By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.”
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 12 – SEC Filing
| CUSIP No. | 737010108 | | Page 12 of 12 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Date: March 30, 2016
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 12 – SEC Filing
Exhibit List
Exhibit A . Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C.(1) Power of Attorney.
(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P., Deerfield PDI Financing, L.P., Deerfield PDI Financing II, L.P., Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield International Master Fund, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Breaking Stick Holdings, LLC, Deerfield Private Design Fund III, L.P. and James E. Flynn.
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 12 – SEC Filing
Exhibit A
Agreement
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Portola Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 12 of 12 – SEC Filing
Exhibit B
Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
